Consent to the Distribution of a New Medicine In the notice published in the New Zealand Gazette, 25 February 1999, No. 23, page 563, notice number 1353, the entries in lines 33 to 38 for Abacavir sulphate are deleted and the following new notice is substituted: Provisional Consent to the Distribution of a New Medicine Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto: Schedule Name and Strength Form Name and Address of Manufacturer Proprietary Name(if any) Abacavir sulphate 23.4mg/mL equivalent to 20 mg/mL abacavir base Solution, oral Glaxo Wellcome Operations, Speke, Liverpool, United Kingdom Ziagen Abacavir sulphate 351 mg equivalent to 300 mg abacavir base Tablet,film coated Glaxo Wellcome Operations, Ware, Hertfordshire, United Kingdom Ziagen Note: This consent is valid for 2 years from the 25th day of February 1999. Dated this 11th day of March 1999. GILLIAN GREW, Chief Advisor, Regulation and Safety (Acting), pursuant to delegation given by the Minister of Health on the 20th day of February 1997.